Vectorite Biomedical Receivables

Vectorite Biomedical (4170.TWO) currently reports a receivables of $5.2M as of June 2026. That compares with $8.8M in the prior-year period — down 41.5% year over year. Use the charts on this page to explore Vectorite Biomedical's receivables history and peer comparisons.

Vectorite Biomedical's receivables decreased from $8.8M to $5.2M — a 41.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Vectorite Biomedical reported $5.2M in receivables as of June 2026. That compares with $8.8M in the prior-year period — down 41.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $5.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vectorite Biomedical, and consider following 4170.TWO for alerts when major investors trade the stock.

Vectorite Biomedical is classified in the Healthcare sector. On receivables, it currently shows $5.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4170.TWO with unrelated industries.